Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial
Eli Lilly (NYSE:LLY) said Wednesday its weight-loss drug Zepbound (tirzepatide) provided a 47% greater relative weight loss ...
Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound ...
Eli Lilly’s stock rises after its Zepbound weight-loss drug achieved better results than ...
Eli Lilly & Co. Inc.’s stock rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk’s Wegovy showed an average weight loss of 20.2% of ...
Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific ...
Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...
BioSpace51 分钟
Amylin Commands Weight-Loss Attention as Industry Anticipates Novo’s Phase III CagriSema ...
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...